These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis. Sayer M; Chapman GB; Thomas M; Dhaun N Curr Rheumatol Rep; 2024 Jan; 26(1):12-23. PubMed ID: 38015334 [TBL] [Abstract][Full Text] [Related]
6. Perinuclear Antineutrophil Cytoplasmic Antibody-Associated Ocular Manifestations: Case Series and Literature Review. Lim YW; Liew OH Ocul Immunol Inflamm; 2024 May; ():1-4. PubMed ID: 38709232 [TBL] [Abstract][Full Text] [Related]
7. ANCA-associated vasculitis presenting with isolated neurological manifestations in a patient with cocaine abuse: a case report and literature review. Aseem F; Lin V; Gilbert AL; Rivadeneira AC; Jennette JC; Bouldin TW; Khoshbakht F; Lee YZ; Chamberlin K; Gelinne A; Mehrabyan AC; Javed B; Dujmovic Basuroski I; Diaz MM Clin Rheumatol; 2024 Apr; 43(4):1401-1407. PubMed ID: 38416306 [TBL] [Abstract][Full Text] [Related]
8. The eye in systemic vasculitis. Menezo V; Lightman S Clin Med (Lond); 2004; 4(3):250-4. PubMed ID: 15244360 [TBL] [Abstract][Full Text] [Related]
9. Treatment goals in ANCA-associated vasculitis: defining success in a new era. Alberici F; Tedesco M; Popov T; Balcells-Oliver M; Mescia F Front Immunol; 2024; 15():1409129. PubMed ID: 38938575 [TBL] [Abstract][Full Text] [Related]
10. Update on antineutrophil cytoplasmic autoantibody vasculitis in children. Bloom JL; Wu EY Curr Opin Rheumatol; 2024 Jul; ():. PubMed ID: 38990100 [TBL] [Abstract][Full Text] [Related]
11. Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies. Karaca I; Tran EM; Park S; Bromeo A; Khojasteh H; Tran ANT; Yavari N; Akhavanrezayat A; Yasar C; Uludag Kirimli G; Than NTT; Hassan M; Or C; Ghoraba H; Do DV; Nguyen QD J Ophthalmic Inflamm Infect; 2024 Mar; 14(1):12. PubMed ID: 38466527 [TBL] [Abstract][Full Text] [Related]
14. Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches. Ford JA; Monach PA Lancet Rheumatol; 2019 Dec; 1(4):e247-e256. PubMed ID: 38229381 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis. Prendecki M; Pusey CD F1000Res; 2018; 7():. PubMed ID: 30079228 [TBL] [Abstract][Full Text] [Related]
16. Reply to Letter "Regarding the hypogammaglobulinemia in invasive fungal infection in ANCA -associated vasculitis. Baliga S; Yadav S; Sagdeo P; Balakrishnan C Clin Rheumatol; 2024 Jun; 43(6):2173-2174. PubMed ID: 38619725 [No Abstract] [Full Text] [Related]
17. Posterior Scleritis: A Case Report and Literature Review of the Management of the Condition. Robertson R; Ansari FA; Gafoor S; Idolor ON; Amakye D Cureus; 2024 Jun; 16(6):e61537. PubMed ID: 38831917 [TBL] [Abstract][Full Text] [Related]
18. Thrombosis in vasculitis: An updated review of etiology, pathophysiology, and treatment. Zhu K; Lv F; Hou X; Wang F; Pang L; Zhong M Heliyon; 2024 Jun; 10(12):e30615. PubMed ID: 38975109 [TBL] [Abstract][Full Text] [Related]
19. Scleritis as the Presenting Sign of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Setting of Temporal Arteritis. Kuang GT; Alryalat SA; Al Deyabat O; Mortensen PW; Lee AG J Neuroophthalmol; 2024 Jun; ():. PubMed ID: 38863111 [No Abstract] [Full Text] [Related]